var data={"title":"Avian influenza A H7N9: Treatment and prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Avian influenza A H7N9: Treatment and prevention</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H19142008\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In late March and April 2013, human cases of severe pneumonia caused by novel avian influenza A H7N9 infection in China were reported to the World Health Organization [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/1-7\" class=\"abstract_t\">1-7</a>]. The number of new cases in the first wave peaked in April and then decreased [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/8\" class=\"abstract_t\">8</a>], likely related, at least in part, to implementation of control strategies including closure of live bird markets and increased public awareness. Since then, annual epidemics have occurred during influenza season; most cases have occurred in China [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/9-12\" class=\"abstract_t\">9-12</a>]. The largest wave has been the fifth wave in late 2016 and early 2017 [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>].</p><p>The treatment and prevention of avian influenza A H7N9 infections will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of avian influenza A H7N9 infections are discussed separately. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;</a>.)</p><p>Other avian influenza viruses (eg, H5N1 influenza) and seasonal influenza viruses are also reviewed separately. (See <a href=\"topic.htm?path=epidemiology-transmission-and-pathogenesis-of-avian-influenza\" class=\"medical medical_review\">&quot;Epidemiology, transmission, and pathogenesis of avian influenza&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-avian-influenza\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of avian influenza&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of avian influenza&quot;</a> and <a href=\"topic.htm?path=avian-influenza-vaccines\" class=\"medical medical_review\">&quot;Avian influenza vaccines&quot;</a> and <a href=\"topic.htm?path=epidemiology-of-influenza\" class=\"medical medical_review\">&quot;Epidemiology of influenza&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-vaccination-in-adults\" class=\"medical medical_review\">&quot;Seasonal influenza vaccination in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-with-vaccines\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention with vaccines&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19143727\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Avian influenza A H7N9 virus appears to be resistant to the adamantanes (<a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a>) but most isolates have been susceptible to the neuraminidase inhibitors (<a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> and <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>) [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/5,12-14\" class=\"abstract_t\">5,12-14</a>]. However, an arginine-to-lysine mutation at position 292 of the neuraminidase protein has been detected in several clinical isolates [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/4,5,15-17\" class=\"abstract_t\">4,5,15-17</a>]. This mutation has been associated with in vitro resistance to neuraminidase inhibitors in another N9 influenza virus [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H19143775\" class=\"local\">'Neuraminidase inhibitor resistance'</a> below.)</p><p>The United States Centers for Disease Control and Prevention (CDC) released updated treatment guidelines for avian influenza A H7N9 infection on September 30, 2013 [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]. The recommendations below are in accordance with the CDC&rsquo;s guidelines. Clinicians should check the <a href=\"http://www.cdc.gov/flu/avianflu/h7n9-virus.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsczTvtrnvMIkLwwT60UzlsQ+r4wr72dT4IG+k4lVrk08wv9cYBAWMcFDxUfCgdK/SA==&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">CDC website</a> for updated recommendations.</p><p class=\"headingAnchor\" id=\"H19143733\"><span class=\"h2\">General recommendations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General recommendations include the following [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Because of the potential severity of illness associated with avian influenza A H7N9 virus infection, we recommend that all confirmed cases, probable cases, and cases under investigation receive antiviral treatment with a neuraminidase inhibitor (<a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> or <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>) as early as possible. Treatment should be initiated even if more than 48 hours has elapsed since illness onset. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing and initiation of antiviral treatment should occur simultaneously; treatment should <strong>not</strong> be delayed for laboratory confirmation of avian influenza A H7N9 virus infection. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H2855411\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">Oseltamivir</a> is recommended for treatment of persons of any age. <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> is recommended for children aged seven years and older. (See <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H5\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Neuraminidase inhibitors'</a>.)</p><p/><p>Evidence regarding the efficacy of the neuraminidase inhibitors for influenza comes from randomized trials, pooled analyses, and observational studies demonstrating decreased time to symptom improvement in patients with uncomplicated seasonal influenza, especially when started within 48 hours of illness onset [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]. Based upon these data, most experts believe that when an antiviral agent is started early in the course of uncomplicated influenza infection, both the duration of symptoms and the likelihood of complications are reduced. Among hospitalized patients with seasonal influenza or avian influenza A H5N1 infection, observational studies suggest that early therapy reduces severity of illness and mortality. Observational studies also support the use of antiviral therapy in hospitalized patients even when started more than 48 hours after onset of illness. (See <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of avian influenza&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of pandemic H1N1 influenza ('swine influenza')&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19143757\"><span class=\"h2\">Hospitalized patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following recommendations apply to avian influenza A H7N9 infections in hospitalized patients [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initiation of antiviral treatment is recommended as early as possible for hospitalized patients with confirmed or probable cases of avian influenza A H7N9 or cases under investigation, even if more than 48 hours has elapsed since illness onset. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For hospitalized patients and patients with severe or complicated avian influenza A H7N9 infection, treatment with oral or enterically administered <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> (and <strong>not</strong> inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>) is recommended because of the lack of data for inhaled zanamivir in patients with severe influenza infection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing and initiation of antiviral therapy should occur simultaneously; treatment should not be delayed while waiting for laboratory testing results. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H2855411\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> is well-absorbed in critically ill patients, for patients who cannot tolerate or absorb oral oseltamivir because of suspected or known gastric stasis, malabsorption, or gastrointestinal bleeding, intravenous (IV) <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> should be considered. IV zanamivir is an investigational parenterally administered product available by enrollment in a clinical trial or compassionate use under an emergency investigational new drug (EIND) request to the manufacturer confirmed with the US Food and Drug Administration. IV zanamivir compassionate use requests can be made by calling the manufacturer at 1-877-626-8019 or 1-866-341-9160. (See <a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza#H412464\" class=\"medical medical_review\">&quot;Treatment and prevention of pandemic H1N1 influenza ('swine influenza')&quot;, section on 'Intravenous zanamivir'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is possible that some avian influenza A H7N9 viruses may become <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> resistant and remain <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> susceptible while on oseltamivir treatment. If a hospitalized patient treated with oseltamivir develops progressive lower respiratory symptoms, resistant virus should be considered, and, after consultation with the CDC, antiviral resistance testing should be performed, IV zanamivir should be started in such situations, and oseltamivir should be stopped. Additional information can be found at the <a href=\"https://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm&amp;token=0/RYeQEqPv++EZ31LJhLr0hjliJ5ynvHa8fpjVUaAtiDUAPdmad6/ARrzllD5NIz667eunPICuNqMTsQFKYUUWuMVQVTnWtGyeVSGsZZ0mo=&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">CDC website</a>. (See <a href=\"#H19143775\" class=\"local\">'Neuraminidase inhibitor resistance'</a> below.)</p><p/><p>Another neuraminidase inhibitor, <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>, has been developed as an IV formulation and has received accelerated authorization by the China State Food and Drug Administration for the treatment of avian influenza A H7N9 infection [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/19\" class=\"abstract_t\">19</a>]. Clinicians in China should consult with national or local public health authorities for specific treatment recommendations. The use of peramivir during the 2009 to 2010 H1N1 influenza A pandemic is discussed separately. (See <a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza#H412471\" class=\"medical medical_review\">&quot;Treatment and prevention of pandemic H1N1 influenza ('swine influenza')&quot;, section on 'Peramivir'</a>.)</p><p>In a study of 111 hospitalized patients with avian influenza A infection, antiviral therapy was initiated in 108 patients (97 percent) at a median of seven days after the onset of illness [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/20\" class=\"abstract_t\">20</a>]. The median time from illness onset and from the initiation of antiviral therapy to a negative real-time reverse transcriptase polymerase chain reaction test on a respiratory specimen was 11 days (interquartile range 9-16 days) and 6 days (interquartile range 4-7 days), respectively. Most patients also received antibacterial agents for pneumonia (71 percent) as well as glucocorticoids (62 percent). </p><p class=\"headingAnchor\" id=\"H19143763\"><span class=\"h3\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual dosing of <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> for the treatment of influenza is 75 mg orally twice daily, and the dosing of <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> is 10 mg (2 inhalations) twice daily (<a href=\"image.htm?imageKey=ID%2F50350\" class=\"graphic graphic_table graphicRef50350 \">table 1</a>). Since oseltamivir is primarily excreted by the kidneys, dosing must be modified for renal insufficiency. (See <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults#H2855204271\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;, section on 'Dosing'</a>.)</p><p>A higher dose of <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> (eg, 150 mg orally twice daily in adults with normal renal function) is recommended by some experts for the treatment of influenza in immunocompromised patients and in severely ill hospitalized patients, although the possible benefit of higher doses remains unknown [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H19143769\"><span class=\"h3\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual duration of antiviral therapy for influenza infection is five days. The following factors should be considered regarding the duration of therapy in hospitalized patients [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The optimal duration and dose of therapy are uncertain in severe or complicated influenza. Pending further data, longer courses of treatment (eg, 10 days of treatment) should be considered for severely ill hospitalized patients. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical judgment and virologic testing of lower respiratory tract specimens by real-time reverse transcriptase polymerase chain reaction should guide decisions regarding whether to extend the duration of therapy for longer than five days for patients with severe and prolonged illness, until viral shedding has ceased. For such patients, lower respiratory tract specimens, such as bronchoalveolar lavage or endotracheal aspirate, are preferred; an oropharyngeal (throat) swab may be collected if lower respiratory specimens are not available. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H2855411\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Longer treatment regimens might be necessary in immunocompromised persons who may have prolonged viral replication and also are at risk of developing antiviral-resistant virus. </p><p/><p class=\"headingAnchor\" id=\"H446878296\"><span class=\"h2\">Uncomplicated illness in outpatients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following recommendations apply to uncomplicated avian influenza A H7N9 infections in outpatients [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A neuraminidase inhibitor should be started as early as possible for outpatients who are confirmed cases, probable cases, or cases under investigation based upon exposure criteria, consisting of contact with a confirmed human avian influenza A H7N9 case. Treatment is <strong>not</strong> currently recommended for outpatients whose exposure consists only of travel to an area with H7N9 cases. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When warranted, antiviral treatment should be initiated, even if more than 48 hours has elapsed since illness onset. Treatment is recommended even for otherwise healthy individuals but is especially important for those at increased risk for influenza complications, such as children &lt;5 years (with highest risk in those aged &lt;2 years), adults aged &gt;65 years, pregnant women, and persons with certain underlying medical conditions (<a href=\"image.htm?imageKey=PEDS%2F72029\" class=\"graphic graphic_table graphicRef72029 \">table 2</a>). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For outpatients with uncomplicated disease in whom fever is absent and symptoms are nearly resolved, the decision to initiate antiviral treatment should be made on a case-by-case basis. Individuals who are not treated with antiviral medications should be monitored for progression of illness.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> is <strong>not</strong> recommended for persons with underlying airway disease (eg, asthma or chronic obstructive pulmonary disease).</p><p/><p class=\"headingAnchor\" id=\"H446878325\"><span class=\"h3\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual dosing of <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> for the treatment of influenza is 75 mg orally twice daily and the dosing of <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> is 10 mg (2 inhalations) twice daily (<a href=\"image.htm?imageKey=ID%2F50350\" class=\"graphic graphic_table graphicRef50350 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]. Since oseltamivir is primarily excreted by the kidneys, dosing must be modified for renal insufficiency. (See <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults#H2855204271\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;, section on 'Dosing'</a>.)</p><p class=\"headingAnchor\" id=\"H446878331\"><span class=\"h3\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The recommended duration of treatment for uncomplicated illness is five days [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H19143775\"><span class=\"h2\">Neuraminidase inhibitor resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, an arginine-to-lysine mutation at position 292 of the neuraminidase (NA) protein (Arg292Lys) has been detected in several clinical isolates of avian influenza A H7N9 [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/4,5,15-17\" class=\"abstract_t\">4,5,15-17</a>]. This mutation has been associated with in vitro resistance to neuraminidase inhibitors in another N9 influenza virus [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. The mutation results in high-level resistance to <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> and reduced susceptibility to <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> and to a greater extent <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a> [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/21\" class=\"abstract_t\">21</a>].<br/><br/>In a study of 14 patients admitted to a hospital in Shanghai in April 2013 with avian influenza A H7N9 infection who were treated with oseltamivir or peramivir, the influenza viral load in throat, stool, serum, and urine specimens was tested serially [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/16\" class=\"abstract_t\">16</a>]. All 14 patients developed pneumonia, 7 required mechanical ventilation, and three continued to worsen and eventually required extracorporeal membrane oxygenation (ECMO). Two of the three patients on ECMO died. Antiviral therapy was associated with a reduction in viral load in throat swab specimens in the 11 patients who survived. The three patients who required ECMO had persistently high viral load in throat swab specimens despite antiviral therapy. The Arg292Lys mutation was detected in two of these three patients; both patients also received glucocorticoids. The glucocorticoids preceded an increase in viral load in two of the patients on ECMO and preceded the emergence of the Arg292Lys mutation in one of these patients. In one of the patients, the wild-type sequence of Arg292 was detected two days after the initiation of antiviral therapy, but the resistant mutant Arg292Lys dominated nine days after the start of therapy. A virus possessing this mutation had 100-fold reduced susceptibility to oseltamivir and 30-fold reduced susceptibility to zanamivir.<br/><br/>In the same study, an arginine-to-lysine mutation at position 152 of the NA protein (Arg152Lys) was detected in one patient requiring mechanical ventilation on day five of treatment [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/16\" class=\"abstract_t\">16</a>]. In a study that used a baculovirus-expressed N9 NA protein, the Arg152Lys mutation was associated with mild resistance to oseltamivir and zanamivir [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/22\" class=\"abstract_t\">22</a>]. </p><p>Four neuraminidase variants each containing a single substitution were recovered from a patient with avian influenza A H7N9 infection who was treated with <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>; one of the mutations led to highly reduced virus inhibition by oseltamivir and <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>, and the three other substitutions led to reduced inhibition by oseltamivir [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/23\" class=\"abstract_t\">23</a>]. </p><p>During the fifth wave of infection that began in late 2016, 7 to 9 percent of H7N9 viruses analyzed to date have had mutations in the neuraminidase gene that confer reduced susceptibility to neuraminidase inhibitors [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>]. Some of the virus specimens may have been collected from patients after a neuraminidase inhibitor had been started.</p><p>DAS181, an investigational recombinant fusion protein with sialidase activity, has shown promise as an antiviral agent; it potently inhibited replication of wild-type avian influenza A H7N9 and Arg292Lys variants in mice [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/24\" class=\"abstract_t\">24</a>].</p><p>Management of patients suspected of being infected with an oseltamivir-resistant virus is discussed above. (See <a href=\"#H19143757\" class=\"local\">'Hospitalized patients'</a> above.)</p><p class=\"headingAnchor\" id=\"H19143781\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Improvements to the public health infrastructure in China have been implemented since the outbreak of severe acute respiratory syndrome coronavirus in 2003; such improvements include rapid disclosure of information regarding outbreaks, expanded capacity of the national disease prevention and control system, use of a large-scale web-based infectious disease reporting system, and international information exchange and collaboration [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/25\" class=\"abstract_t\">25</a>]. In an attempt to limit the transmission of avian influenza A H7N9 from poultry to humans, live poultry transactions have been suspended in some parts of China [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/26\" class=\"abstract_t\">26</a>]. Such closures have likely contributed to reducing the number of cases; as of June 1, 2013, no new cases had been reported since May 5 in Shanghai, Nanjing, or Hangzhou, cities that undertook complete closure of live poultry markets [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/25\" class=\"abstract_t\">25</a>]. One study suggested that closure of live poultry markets in Shanghai, Hangzhou, Huzhou, and Nanjing, where most human infections occurred, reduced the mean daily number of infections in these cities by 97 to 99 percent [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Some experts have advocated the implementation of other measures in China, such as vaccinating poultry on farms, prohibiting the transport of live birds, and restructuring the live poultry market system [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/28-30\" class=\"abstract_t\">28-30</a>]. Other methods to prevent infection are discussed below.</p><p class=\"headingAnchor\" id=\"H19143787\"><span class=\"h2\">Infection control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The United States Centers for Disease Control and Prevention (CDC) recommends a higher level of infection control than that used for seasonal influenza viruses [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/31\" class=\"abstract_t\">31</a>]. In particular, when caring for patients with confirmed or probable avian influenza A H7N9 infection or for patients under investigation for avian influenza A H7N9 infection, healthcare workers should use eye protection and respirators (eg, N95 masks) in addition to standard, droplet, and contact precautions. Such patients should be placed in airborne infection isolation rooms. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p>Additional recommendations regarding infection control measures for healthcare settings can be found at the <a href=\"https://www.cdc.gov/flu/avianflu/novel-flu-infection-control.htm&amp;token=XGdjYlJ+AZO2ia0IdCbCXqwHoWTmu5mmYxQApgQnExYZjjscAgwgjfpwaK9D1qYabcaN0skgzf3Y3x5+igLEPd1YVbvP/g8SfXhEN2xWn6c=&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">CDC website</a>. Recommendations for working with avian influenza A H7N9 can also be found at the <a href=\"http://www.cdc.gov/flu/avianflu/h7n9/risk-assessment.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsczTvtrnvMIkLwwT60UzlsQETUk4wm4uF+gsFZb/K3ZBMWZIdQn18XPUEuS+7k7hUg==&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">CDC website</a> [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/32\" class=\"abstract_t\">32</a>]. </p><p class=\"headingAnchor\" id=\"H19143793\"><span class=\"h2\">Postexposure prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The CDC released guidelines for chemoprophylaxis of close contacts of patients with avian influenza A H7N9 infection on September 30, 2013 [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]. These recommendations are based upon available information and the fact that there is no available H7N9 vaccine, the virus has caused severe disease and substantial mortality, limited nonsustained human-to-human transmission may have occurred in some case clusters in China, and sufficient supplies of antiviral agents expected to be effective against H7N9 are available.</p><p>The CDC recommends the following approach to postexposure prophylaxis [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">Oseltamivir</a> or inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> chemoprophylaxis should be provided to close contacts of a confirmed or probable H7N9 case patient who have had a substantial risk of exposure:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In high-risk exposure groups, chemoprophylaxis should be administered. High-risk exposure groups are defined as household or close family member contacts of a confirmed or probable case.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In moderate-risk exposure groups, chemoprophylaxis could be considered. Moderate-risk exposure groups include healthcare workers with contact with a confirmed or probable case during bronchoscopy or intubation; while performing tracheal suctioning, delivering nebulized drugs, or handling inadequately screened or sealed body fluids without use of recommended personal protective equipment (PPE); or following a recognized breach in PPE procedures.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In low-risk exposure groups, chemoprophylaxis is <strong>not</strong> routinely recommended. Low-risk exposure groups include those who have had social contact of a short duration with a confirmed or probable case in a nonhospital setting (eg, in a community or workplace environment).</p><p/><p class=\"bulletIndent2\">The definition of close contacts is presented separately. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decisions to initiate antiviral chemoprophylaxis for persons in moderate- and low-risk exposure groups should be based upon clinical judgment, with consideration given to the type of exposure and to whether the close contact is at high risk for complications from influenza (<a href=\"image.htm?imageKey=PEDS%2F72029\" class=\"graphic graphic_table graphicRef72029 \">table 2</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administration of chemoprophylaxis should begin as soon as possible after exposure to the confirmed or probable case.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment dose for neuraminidase inhibitors (two doses per day) is recommended instead of the typical chemoprophylaxis regimen (one dose per day). The dosing for <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> should be 75 mg orally twice daily. The dosing for <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> should be 10 mg (2 inhalations) twice daily. This recommendation is based upon limited data that support higher chemoprophylaxis dosing in animals with avian H5N1 influenza A virus infection and on the desire to prevent development of antiviral resistance while receiving chemoprophylaxis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chemoprophylaxis should be continued for 5 or 10 days. If exposure was time-limited and not ongoing, 5 days of medication from the last known exposure is recommended. If exposure is likely to be ongoing (eg, household setting), 10 days is recommended because of the potential for prolonged infectiousness in the case-patient.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> is recommended for persons of any age including newborn infants; inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> is recommended for persons aged seven years and older. Inhaled zanamivir is not recommended for persons with underlying airway disease (eg, asthma or chronic obstructive pulmonary disease). The contraindications and adverse effects of these agents are discussed in detail separately. (See <a href=\"topic.htm?path=pharmacology-of-antiviral-drugs-for-influenza\" class=\"medical medical_review\">&quot;Pharmacology of antiviral drugs for influenza&quot;</a>.)</p><p/><p>The use of postexposure prophylaxis for seasonal influenza is discussed separately. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H364077882\"><span class=\"h2\">Treatment of symptomatic close contacts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic close contacts should be promptly tested for avian influenza H7N9 virus infection and should simultaneously be treated with a neuraminidase inhibitor [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"#H19143727\" class=\"local\">'Treatment'</a> above.)</p><p>Symptomatic individuals should stay home except to seek medical care and should limit contact with other persons until their illness is resolved [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H364077928\"><span class=\"h2\">Patients who develop symptoms after use of an antiviral agent</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If a close contact becomes symptomatic or has worsening of symptoms after or during use of an antiviral agent, contact with other persons should be minimized, appropriate infection prevention and control measures should be used in healthcare settings, and respiratory specimens should be collected for avian influenza A H7N9 virus testing at the state health department as soon as possible [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>].</p><p>If a close contact tests positive for avian influenza A H7N9 virus after taking <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> chemoprophylaxis for more than two days, <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> should be started (10 mg [2 inhalations] twice daily) as soon as possible, and oseltamivir should be stopped because some avian influenza A H7N9 viruses may rapidly become oseltamivir-resistant and remain zanamivir-susceptible [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]. If the patient develops progressive lower respiratory symptoms, the patient should be hospitalized promptly for treatment with investigational intravenous (IV) zanamivir, available by enrollment in a clinical trial or compassionate use under an emergency investigational new drug (EIND) request. An IV zanamivir compassionate use request may be made by contacting the manufacturer at 1-877-626-8019 or 1-866-341-9160.</p><p>Investigation for antiviral resistance should be initiated immediately, and infection prevention and control measures recommended for patients with avian influenza A H7N9 infection should be implemented. (See <a href=\"#H19143787\" class=\"local\">'Infection control'</a> above.)</p><p>The definition of close contacts is presented separately. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p class=\"headingAnchor\" id=\"H389599911\"><span class=\"h2\">Follow-up of close contacts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The CDC recommends that public health personnel attempt to identify and monitor all close contacts of confirmed or probable cases of avian influenza A H7N9 infection for new illness as soon as possible [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]. Identified close contacts should be monitored daily for 10 days after the last known exposure to a confirmed or probable case. Measured temperature and presence of respiratory symptoms should be assessed daily during this period. Any close contacts of a confirmed or probable case with a measured temperature of &ge;38.0&deg;C (&ge;100.4&deg; F) or any new respiratory symptoms (eg, cough, sore throat, shortness of breath, difficulty breathing) should be referred for prompt medical evaluation and testing for avian influenza A H7N9 virus infection. To facilitate investigation, and if resources are available, close contacts of cases under investigation may also be identified and monitored for symptoms while the results of laboratory testing are pending.</p><p>The definition of close contacts is presented separately. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H3096574\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Case definitions'</a>.)</p><p class=\"headingAnchor\" id=\"H19143805\"><span class=\"h2\">Vaccine development</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The CDC helped to develop a candidate avian influenza A H7N9 vaccine virus strain should a vaccine become necessary [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The World Health Organization (WHO) recommended that an <span class=\"nowrap\">A/Anhui/1/2013-like</span> virus be used for vaccine development [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/36\" class=\"abstract_t\">36</a>]. Should the decision be made to produce a vaccine, it is expected to take several months until it would be available for clinical use [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/37,38\" class=\"abstract_t\">37,38</a>]. In the event that avian influenza A H7N9 causes a pandemic, to substantially reduce infections, deaths, and influenza-associated treatment costs, vaccination would need to be completed more quickly than the nine months it took for a vaccine to become available during the 2009 to 2010 H1N1 influenza pandemic [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Viruses isolated during the fifth wave in late 2016 and early 2017 belong to two distinct lineages, the Pearl River Delta and Yangtze River Delta lineages [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>]. Among 74 hemagglutinin gene sequences tested, 69 (93 percent) have been Yangtze River Delta lineage viruses. Preliminary data suggest that Yangtze River Delta viruses have reduced cross-reactivity with existing candidate vaccine viruses, whereas Pearl River delta viruses are well inhibited by antisera raised to candidate vaccine viruses. These results indicate that the Yangtze River Delta lineage viruses are antigenically distinct from earlier H7N9 viruses. In March 2017, the World Health Organization recommended that two new candidate virus vaccines be developed. </p><p>Several trials have shown that adjuvanted avian influenza A H7N9 vaccines are far more immunogenic than non-adjuvanted vaccines [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/40-43\" class=\"abstract_t\">40-43</a>].</p><p>Examples of trials showing that adjuvanted vaccines are more immunogenic than non-adjuvanted vaccines include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial that included adults, two doses of an experimental virus-like particle (VLP) avian influenza A H7N9 vaccine containing a saponin-based ISCOMATRIX adjuvant resulted in seroconversion rates as high as 81 percent, compared with only 6 to 16 percent for a non-adjuvanted VLP vaccine [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a phase II randomized trial, adults were given two immunizations with an experimental inactivated avian influenza A H7N9 vaccine at one of four doses of hemagglutinin with or without MF59 adjuvant [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/41\" class=\"abstract_t\">41</a>]. In those who received the non-adjuvanted vaccine, hemagglutinin inhibition antibodies were minimal. After receiving two immunizations with adjuvanted H7N9 vaccine at the lowest dose (3.75 mcg), seroconversion (a minimum fourfold increase to titer 1:40) occurred in 59 percent of participants. Higher antigen doses were not associated with increased responses. Adverse reactions were generally mild, with more injection site reactions in those who received MF59.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a phase II randomized trial, adults were given two doses of an experimental inactivated avian influenza A H7N9 vaccine containing varying doses of hemagglutinin with or without AS03 or MF59 adjuvant [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/42\" class=\"abstract_t\">42</a>]. Two doses were required to elicit detectable antibody titers in most individuals. After receiving two doses of vaccine containing 15 mcg of hemagglutinin, the proportion of individuals achieving a hemagglutinin titer &ge;1:40 was 2 percent without adjuvant, 57 percent with MF59 adjuvant, and 84 percent with AS03 adjuvant. Schedules that alternated the AS03- and MF59-adjuvanted formulations led to lower geometric mean titers than schedules that used two doses of AS03- or MF59-adjuvanted formulations. The schedules that included two doses of an AS03-adjuvanted vaccine resulted in the highest geometric mean titers. Among the individuals who received two doses of AS03-adjuvanted vaccine, hemagglutinin content (3.75, 7.5, or 15 mcg) was not associated with statistically significant differences in the proportion of participants with a titer &ge;1:40.</p><p/><p>A prime-boost regimen involving administration of a live-attenuated H7N9 influenza A vaccine followed by a non-adjuvanted inactivated H7N9 influenza A vaccine has also been evaluated and appears to be immunogenic [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Other avian influenza vaccines are discussed separately. (See <a href=\"topic.htm?path=avian-influenza-vaccines\" class=\"medical medical_review\">&quot;Avian influenza vaccines&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19143811\"><span class=\"h2\">Travel information</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The WHO does not advise special screening for avian influenza A H7N9 at points of entry, nor does it recommend that any travel or trade restrictions be applied [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/45\" class=\"abstract_t\">45</a>]. The CDC has released hygiene and food safety <a href=\"http://wwwnc.cdc.gov/travel/notices/watch/avian-flu-h7n9-china.htm&amp;token=9DZM/Vd+nkTyEGl5Y8POv23EBRfAaZPqaTvqVITtoBGV0XQ9UZZGtMdsRkCK0ni4NH6FO2V1Ob4uGNplK7eIEVajW7c2Y92YuZjOPm0lt74=&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">recommendations</a> to prevent the transmission of avian influenza A H7N9 in China [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H19143817\"><span class=\"h1\">OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As of December 2016, 808 laboratory-confirmed cases had been reported since the virus emerged in 2013, including 322 deaths (40 percent) [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/47\" class=\"abstract_t\">47</a>]. In an analysis that used China&rsquo;s national integrated database to evaluate approximately 130 cases of laboratory-confirmed avian influenza A H7N9 requiring hospitalization, the estimated fatality risk on hospital admission was 36 percent (compared with 70 percent for avian influenza A H5N1) [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/8,48\" class=\"abstract_t\">8,48</a>]. The fatality risk was substantially higher for individuals &ge;60 years of age compared with younger individuals (49 versus 18 percent) [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Extrapolating from data regarding mild cases detected by routine surveillance for influenza-like illness at sentinel sites and information about healthcare-seeking behavior observed during the 2009 H1N1 influenza A pandemic, the symptomatic case-fatality rate was estimated to be between 160 and 2800 per 100,000 symptomatic cases [<a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/48\" class=\"abstract_t\">48</a>]. This estimate is substantially lower than the observed fatality risk, suggesting that many mild cases may have occurred but were not detected during early case ascertainment.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=bird-flu-avian-influenza-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Bird flu (avian influenza) (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H19144735\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In late March and April 2013, human cases of severe pneumonia caused by novel avian influenza A H7N9 in China were reported to the World Health Organization (WHO). The number of new cases during the first wave peaked in April 2013 and then declined, likely related, at least in part, to implementation of control strategies including closure of live bird markets and increased public awareness. A rise in the number of cases occurred in late 2013 and early 2014 as well as in late 2014 and early 2015, coinciding with influenza season. Cases continue to be detected. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H2853520\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Epidemiology'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avian influenza A H7N9 viruses appear to be resistant to the adamantanes (<a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a>) but susceptible to the neuraminidase inhibitors (<a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> and <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>). Some isolates have become resistant to neuraminidase inhibitors during therapy. (See <a href=\"#H19143727\" class=\"local\">'Treatment'</a> above and <a href=\"#H19143775\" class=\"local\">'Neuraminidase inhibitor resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing and initiation of antiviral treatment should occur simultaneously; treatment should <strong>not</strong> be delayed for laboratory confirmation of avian influenza A H7N9 virus infection. (See <a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis#H2855411\" class=\"medical medical_review\">&quot;Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For hospitalized patients with confirmed or probable avian influenza A H7N9 or for hospitalized cases under investigation, we recommend treatment with oral <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> (and not inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). For patients who cannot tolerate or absorb oral oseltamivir because of suspected or known gastric stasis, malabsorption, or gastrointestinal bleeding, an intravenous (IV) neuraminidase inhibitor (eg, zanamivir, <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>) can be used; clinicians should consult their national or local public health authorities for country-specific recommendations regarding the use of IV neuraminidase inhibitors. Treatment should be started as early as possible, even if more than 48 hours has elapsed since illness onset. (See <a href=\"#H19143757\" class=\"local\">'Hospitalized patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For outpatients with confirmed or probable avian influenza A H7N9 infection or for outpatient cases under investigation, we recommend prompt initiation of oral <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> or inhaled <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>, even if more than 48 hours has elapsed since illness onset and even for apparently uncomplicated illness (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H446878296\" class=\"local\">'Uncomplicated illness in outpatients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When caring for patients with confirmed or probable avian influenza A H7N9 infection or for patients under investigation for avian influenza A H7N9 infection, healthcare workers should use eye protection and respirators (eg, N95 masks) in addition to standard precautions. (See <a href=\"#H19143787\" class=\"local\">'Infection control'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postexposure antiviral prophylaxis is recommended for certain individuals. Detailed recommendations are provided above. (See <a href=\"#H19143793\" class=\"local\">'Postexposure prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although no avian influenza A H7N9 vaccine is currently available, several experimental adjuvanted vaccines are immunogenic. (See <a href=\"#H19143805\" class=\"local\">'Vaccine development'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Updated information can be found at the <a href=\"http://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/index.html&amp;token=4ologJYWhO4Dacm+CtATL1zSw0pC7fXVqP2FEwVcRhY9N87sX5doVfD6TG8lb83MYl50t1uZ30ak2CfibxyC8U3mBc7W79C3aIdNOoT13M4=&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">WHO website</a> and <a href=\"http://www.cdc.gov/flu/avianflu/h7n9-virus.htm&amp;token=mjmpv7xMHRIW2nr+3NCnsczTvtrnvMIkLwwT60UzlsQ+r4wr72dT4IG+k4lVrk08wv9cYBAWMcFDxUfCgdK/SA==&amp;TOPIC_ID=89700\" target=\"_blank\" class=\"external\">CDC website</a>.</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">World Health Organization. Global alert and response. H7N9 avian influenza human infections in China. http://www.who.int/csr/don/2013_04_01/en/index.html (Accessed on April 03, 2013).</li><li class=\"breakAll\">World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. http://www.who.int/csr/don/2013_04_04/en/index.html (Accessed on April 04, 2013).</li><li class=\"breakAll\">World Health Organization. Global alert and response. Human infection with influenza A(H7N9) in China &ndash; update. http://www.who.int/csr/don/2013_04_03/en/index.html (Accessed on April 03, 2013).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/4\" class=\"nounderline abstract_t\">Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/5\" class=\"nounderline abstract_t\">Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med 2013; 368:1862.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/6\" class=\"nounderline abstract_t\">Li Q, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014; 370:520.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/7\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013. MMWR Morb Mortal Wkly Rep 2013; 62:366.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/8\" class=\"nounderline abstract_t\">Cowling BJ, Jin L, Lau EH, et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 2013; 382:129.</a></li><li class=\"breakAll\">World Health Organization. Influenza at the human-animal interface. Summary and assessment, 4 October to 21 November 2016. http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_11_15_2016.pdf?ua=1 (Accessed on November 30, 2016).</li><li class=\"breakAll\">World Health Organization. Human infection with avian influenza A(H7N9) virus &ndash; China. http://www.who.int/csr/don/17-january-2017-ah7n9- (Accessed on January 17, 2017).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/11\" class=\"nounderline abstract_t\">Xiang N, Li X, Ren R, et al. Assessing Change in Avian Influenza A(H7N9) Virus Infections During the Fourth Epidemic - China, September 2015-August 2016. MMWR Morb Mortal Wkly Rep 2016; 65:1390.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/12\" class=\"nounderline abstract_t\">Iuliano AD, Jang Y, Jones J, et al. Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017. MMWR Morb Mortal Wkly Rep 2017; 66:254.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/13\" class=\"nounderline abstract_t\">Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499:500.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/14\" class=\"nounderline abstract_t\">Baranovich T, Burnham AJ, Marathe BM, et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 2014; 209:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/15\" class=\"nounderline abstract_t\">Kageyama T, Fujisaki S, Takashita E, et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18:20453.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/16\" class=\"nounderline abstract_t\">Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/17\" class=\"nounderline abstract_t\">Lin PH, Chao TL, Kuo SW, et al. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan. Clin Infect Dis 2014; 58:242.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim guidance on the use of antiviral agents for treatment of human infections with avian influenza A (H7N9) virus. http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm (Accessed on October 14, 2013).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/19\" class=\"nounderline abstract_t\">From SARS to H7N9: will history repeat itself? Lancet 2013; 381:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/20\" class=\"nounderline abstract_t\">Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/21\" class=\"nounderline abstract_t\">Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet 2013; 381:2230.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/22\" class=\"nounderline abstract_t\">Z&uuml;rcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006; 58:723.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/23\" class=\"nounderline abstract_t\">Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis 2015; 211:249.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/24\" class=\"nounderline abstract_t\">Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 2014; 210:435.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/25\" class=\"nounderline abstract_t\">Wang Y. The H7N9 influenza virus in China--changes since SARS. N Engl J Med 2013; 368:2348.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/26\" class=\"nounderline abstract_t\">Wu S, Wu F, He J. Emerging risk of H7N9 influenza in China. Lancet 2013; 381:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/27\" class=\"nounderline abstract_t\">Yu H, Wu JT, Cowling BJ, et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet 2014; 383:541.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/28\" class=\"nounderline abstract_t\">Xu J, Lu S, Wang H, Chen C. Reducing exposure to avian influenza H7N9. Lancet 2013; 381:1815.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/29\" class=\"nounderline abstract_t\">Lee SS, Wong NS, Leung CC. Exposure to avian influenza H7N9 in farms and wet markets. Lancet 2013; 381:1815.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/30\" class=\"nounderline abstract_t\">Fourni&eacute; G, Pfeiffer DU. Can closure of live poultry markets halt the spread of H7N9? Lancet 2014; 383:496.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim guidance for infection control within healthcare settings when caring for patients with confirmed, probable, or cases under investigation of avian influenza A(H7N9) virus infection. http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm (Accessed on April 30, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim risk assessment and biosafety level recommendations for working with influenza A(H7N9) viruses. http://www.cdc.gov/flu/avianflu/h7n9/risk-assessment.htm (Accessed on June 10, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim guidance on the use of antiviral medications for chemoprophylaxis of close contacts of persons with avian influenza A (H7N9) virus infection. http://www.cdc.gov/flu/avianflu/h7n9-av-chemoprophylaxis-guidance.htm (Accessed on October 14, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Additional H7N9 cases reported in China; CDC receives H7N9 virus isolate. http://www.cdc.gov/flu/spotlights/h7n9-cases-china.htm (Accessed on April 15, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. H7N9 situation and CDC response update. http://www.cdc.gov/flu/spotlights/h7n9-cdc-response.htm (Accessed on May 17, 2013).</li><li class=\"breakAll\">World Health Organization. WHO provisional recommendation on influenza A(H7N9) vaccine virus. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/ProvisionalRecommendation_H7N9_31May13.pdf (Accessed on June 07, 2013).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/37\" class=\"nounderline abstract_t\">Osterholm MT, Ballering KS, Kelley NS. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 2013; 309:2557.</a></li><li class=\"breakAll\">World Health Organization. Overview of the emergence and characteristics of the avian influenza A(H7N9) virus. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/WHO_H7N9_review_31May13.pdf (Accessed on June 06, 2013).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/39\" class=\"nounderline abstract_t\">Khazeni N, Hutton DW, Collins CI, et al. Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study. Ann Intern Med 2014; 160:684.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/40\" class=\"nounderline abstract_t\">Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/41\" class=\"nounderline abstract_t\">Mulligan MJ, Bernstein DI, Winokur P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1409.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/42\" class=\"nounderline abstract_t\">Jackson LA, Campbell JD, Frey SE, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA 2015; 314:237.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/43\" class=\"nounderline abstract_t\">Madan A, Segall N, Ferguson M, et al. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. J Infect Dis 2016; 214:1717.</a></li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/44\" class=\"nounderline abstract_t\">Sobhanie M, Matsuoka Y, Jegaskanda S, et al. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis 2016; 213:922.</a></li><li class=\"breakAll\">World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. http://www.who.int/csr/don/2013_04_15/en/index.html (Accessed on April 16, 2013).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Travelers' Health - Avian flu (H7N9) in China. http://wwwnc.cdc.gov/travel/notices/watch/avian-flu-h7n9-china.htm (Accessed on April 23, 2013).</li><li class=\"breakAll\">World Health Organization. Influenza at the human-animal interface. Summary and assessment, 22 November to 19 December 2016. http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_12_19_2016.pdf?ua=1 (Accessed on January 17, 2017).</li><li><a href=\"https://www.uptodate.com/contents/avian-influenza-a-h7n9-treatment-and-prevention/abstract/48\" class=\"nounderline abstract_t\">Yu H, Cowling BJ, Feng L, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 2013; 382:138.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 89700 Version 28.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H19144735\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H19142008\" id=\"outline-link-H19142008\">INTRODUCTION</a></li><li><a href=\"#H19143727\" id=\"outline-link-H19143727\">TREATMENT</a><ul><li><a href=\"#H19143733\" id=\"outline-link-H19143733\">General recommendations</a></li><li><a href=\"#H19143757\" id=\"outline-link-H19143757\">Hospitalized patients</a><ul><li><a href=\"#H19143763\" id=\"outline-link-H19143763\">- Dosing</a></li><li><a href=\"#H19143769\" id=\"outline-link-H19143769\">- Duration</a></li></ul></li><li><a href=\"#H446878296\" id=\"outline-link-H446878296\">Uncomplicated illness in outpatients</a><ul><li><a href=\"#H446878325\" id=\"outline-link-H446878325\">- Dosing</a></li><li><a href=\"#H446878331\" id=\"outline-link-H446878331\">- Duration</a></li></ul></li><li><a href=\"#H19143775\" id=\"outline-link-H19143775\">Neuraminidase inhibitor resistance</a></li></ul></li><li><a href=\"#H19143781\" id=\"outline-link-H19143781\">PREVENTION</a><ul><li><a href=\"#H19143787\" id=\"outline-link-H19143787\">Infection control</a></li><li><a href=\"#H19143793\" id=\"outline-link-H19143793\">Postexposure prophylaxis</a></li><li><a href=\"#H364077882\" id=\"outline-link-H364077882\">Treatment of symptomatic close contacts</a></li><li><a href=\"#H364077928\" id=\"outline-link-H364077928\">Patients who develop symptoms after use of an antiviral agent</a></li><li><a href=\"#H389599911\" id=\"outline-link-H389599911\">Follow-up of close contacts</a></li><li><a href=\"#H19143805\" id=\"outline-link-H19143805\">Vaccine development</a></li><li><a href=\"#H19143811\" id=\"outline-link-H19143811\">Travel information</a></li></ul></li><li><a href=\"#H19143817\" id=\"outline-link-H19143817\">OUTCOMES</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H3685230973\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H19144735\" id=\"outline-link-H19144735\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/89700|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/50350\" class=\"graphic graphic_table\">- Antivirals for influenza</a></li><li><a href=\"image.htm?imageKey=PEDS/72029\" class=\"graphic graphic_table\">- Groups at high risk for influenza complications</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=avian-influenza-a-h7n9-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Avian influenza A H7N9: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=avian-influenza-vaccines\" class=\"medical medical_review\">Avian influenza vaccines</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-avian-influenza\" class=\"medical medical_review\">Clinical manifestations and diagnosis of avian influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">Clinical manifestations of seasonal influenza in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">Diagnosis of seasonal influenza in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-influenza\" class=\"medical medical_review\">Epidemiology of influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-transmission-and-pathogenesis-of-avian-influenza\" class=\"medical medical_review\">Epidemiology, transmission, and pathogenesis of avian influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bird-flu-avian-influenza-the-basics\" class=\"medical medical_basics\">Patient education: Bird flu (avian influenza) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-antiviral-drugs-for-influenza\" class=\"medical medical_review\">Pharmacology of antiviral drugs for influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">Prevention of seasonal influenza with antiviral drugs in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Seasonal influenza in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">Seasonal influenza in children: Prevention and treatment with antiviral drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-with-vaccines\" class=\"medical medical_review\">Seasonal influenza in children: Prevention with vaccines</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-vaccination-in-adults\" class=\"medical medical_review\">Seasonal influenza vaccination in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">Treatment and prevention of avian influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza\" class=\"medical medical_review\">Treatment and prevention of pandemic H1N1 influenza ('swine influenza')</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">Treatment of seasonal influenza in adults</a></li></ul></div></div>","javascript":null}